<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04622579</url>
  </required_header>
  <id_info>
    <org_study_id>2020099H</org_study_id>
    <nct_id>NCT04622579</nct_id>
  </id_info>
  <brief_title>Lenalidomide Combined With Rituximab as Front-line Therapy for DLBCL Patients Aged Over 80 Years</brief_title>
  <acronym>R2DLBCL80</acronym>
  <official_title>Lenalidomide Combined With Rituximab as Front-line Therapy in Elderly Patients Aged Over 80 Years With Diffuse Large B Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guangzhou First People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Foshan First People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huizhou Municipal Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shantou Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guangdong Provincial People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      About 40% of Diffuse large B cell lymphoma relapse or is refractory, age is a prognostic&#xD;
      factor of DLBCL, as elderly patients are not capable to received standard treatment, the&#xD;
      prognosis of elderly patients is poor especially those aged over 80 years. In this study,we&#xD;
      aimed to investigate the safety and efficacy of the combination of lenalidomide and rituximab&#xD;
      in elderly patients aged ≥ 80 years with untreated DLBCL.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 23, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>24 months</time_frame>
    <description>Overall response rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CR</measure>
    <time_frame>24 months</time_frame>
    <description>Complete response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>from date of treatment until the date of death from any cause, assessed up to 5 years</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>from date of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years</time_frame>
    <description>Progression-free survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <condition>Age Over 80 Years</condition>
  <arm_group>
    <arm_group_label>lenalidomide combined with rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rituximab 375 mg/m2 i.v d1 q28d； Lenalidomide 10mg Po. d1-21 q28d. After 6 cycles, patients obtained CR or PR will continue with Lenalidomide maintenance till the 24th month.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lenalidomide combined with rituximab</intervention_name>
    <description>lenalidomide and rituximab are dilivered as described, parameters concerning efficacy and safety are also obtained.</description>
    <arm_group_label>lenalidomide combined with rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age≧80 years ;&#xD;
&#xD;
          2. ECOG score 0-2；&#xD;
&#xD;
          3. untreated with pathologically conﬁrmed CD20+ DLBCL ;&#xD;
&#xD;
          4. expected life expectancy of ≥ 12 weeks;&#xD;
&#xD;
          5. capable of swallowing tablets;&#xD;
&#xD;
          6. GFR(by Cockcroft- Gault)≥30 ml/min;&#xD;
&#xD;
          7. can sign written informed consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. with CNS involvement;&#xD;
&#xD;
          2. with other malignancy (not including adequate-treated non-melanoma cutaneum&#xD;
             carcinoma); patients with other cancer but disease-free for ≥5 years can enter this&#xD;
             study;&#xD;
&#xD;
          3. with ≥ grade 2 peripheral neurophathy;&#xD;
&#xD;
          4. with cardiopathy including unstable angia or myocardial infarction over the past 8&#xD;
             weeks;&#xD;
&#xD;
          5. received live vaccine within 28 days.;&#xD;
&#xD;
          6. HIV-positive;&#xD;
&#xD;
          7. thrombosis ;&#xD;
&#xD;
          8. GFR&lt;30 mL/min;&#xD;
&#xD;
          9. other conditions not suitable for rituximab or lenalidomide application.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>80 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xinmiao Jiang</last_name>
    <phone>（+86）20-83827812</phone>
    <email>296260860@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guangdong provincial people's hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinmiao Jiang</last_name>
      <phone>+86 20 81884713-80631</phone>
      <email>296260860@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 5, 2020</study_first_submitted>
  <study_first_submitted_qc>November 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2020</study_first_posted>
  <last_update_submitted>November 5, 2020</last_update_submitted>
  <last_update_submitted_qc>November 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangdong Provincial People's Hospital</investigator_affiliation>
    <investigator_full_name>Wenyu Li</investigator_full_name>
    <investigator_title>professor of medicine</investigator_title>
  </responsible_party>
  <keyword>lenalidomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

